Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements Abstract #1857

Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.
Aim(s): To determine which markers are associated with total NET burden.
Materials and methods: A retrospective analysis of a prospective database of patients with NETs (n=232). Fasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP), and 24-hour urinary 5-hydroxyindoleacetic acid (5HIAA) levels were measured.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Keywords: PET burden

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1855 Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)
Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Amit Tirosh
#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study
Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rachelle Steyn
Authors: Steyn R, Prasad V, ...
#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Dr Amit Tirosh
#315 The Impact of 68Ga-DOTATOC PET/CT on the Multimodal Management of Patients with Neuroendocrine Tumors
Introduction: Accurate assessment of the primary tumor site and the extent of the metastatic burden are crucial and can be challenging, however, it is essential to the choice of optimal patient-tailored management.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Andrea Frilling
#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Song
Authors: Song H, Kunz P, Fisher G, Franc B, ...